Global Peptide Synthesis Market Outlook Report 2026-2035 Set To Reach USD 7 Billion By 2035, Driven By GLP-1 Demand And Manufacturing Capacity Expansion
The global peptide synthesis market is projected to grow from USD 4.4 billion in 2026 to USD 7 billion by 2035, registering a compound annual growth rate of 5.2% during the forecast period. Market expansion is being supported by the growing peptide therapeutics pipeline, rising demand for peptide active pharmaceutical ingredients (APIs), continued investment in manufacturing infrastructure, and increased outsourcing to specialized contract development and manufacturing organizations (CDMOs).
Peptide therapeutics have gained significant commercial and clinical momentum due to their metabolic stability, biological target specificity, and binding affinity. Regulatory authorities worldwide have approved nearly 100 peptide-based therapies across major indications, including cancer, diabetes, chronic pain, HIV infection, multiple sclerosis, and osteoporosis.
Demand is accelerating particularly rapidly for GLP-1 and GIP receptor agonists used in diabetes and obesity treatment. The increasing volume and complexity of these drug candidates have intensified pressure on global peptide API manufacturing capacity. Pharmaceutical and biotechnology companies are consequently outsourcing more clinical and commercial production to peptide CDMOs to reduce capital requirements, access specialized technologies, and accelerate product development timelines.
Manufacturing Investment Reshapes the Peptide Synthesis Market
Leading peptide manufacturers are expanding solid phase, liquid phase, and hybrid synthesis capacity while upgrading purification systems and introducing automated and AI-assisted process controls. CordenPharma, PolyPeptide, Cambrex, and other industry participants have announced major facility investments designed to address supply constraints and support next-generation peptide therapeutics.
CordenPharma has committed more than EUR 900 million to capacity investment, while PolyPeptide is doubling capacity at its Malmo site and Cambrex is expanding its facility in Waltham, Massachusetts. CordenPharma's multi-year agreement with Viking Therapeutics for commercial manufacturing of the GLP-1/GIP candidate VK2735 also demonstrates the growing importance of large-scale peptide supply partnerships.
Market consolidation is creating additional competitive momentum. Granules India's acquisition of Senn Chemicals in April 2025 reflects a broader trend in which diversified pharmaceutical companies are entering the peptide CDMO market through targeted transactions. Agreements involving Hybio Pharmaceutical, iCarbonX Intelligent Peptide, and Sunshine Mandi Pharmaceutical further highlight rising reliance on outsourced peptide development and commercial API production.
Technology and Sustainability Support Long-Term Growth
Advances in solid phase peptide synthesis, liquid phase peptide synthesis, hybrid production, microwave-assisted processing, chemo-enzymatic synthesis, and continuous flow technology are improving scalability, productivity, and cost efficiency. Hybrid synthesis is expected to record particularly strong growth because of its suitability for longer peptide sequences and structurally complex molecules.
Sustainability is also becoming an important factor in CDMO selection. Traditional peptide manufacturing requires substantial solvent and resource use, increasing demand for greener production methods. EUROAPI's collaboration with StrainChem on sustainable liquid phase peptide synthesis and Innovate UK's EUR 913,659 investment in sustainable GLP-1 biomanufacturing illustrate the industry's growing focus on green chemistry.
Despite favorable market conditions, manufacturers continue to face capacity shortages, supply bottlenecks, high infrastructure costs, and technical challenges associated with complex, high-volume peptides. Geographic concentration of manufacturing facilities also exposes the peptide supply chain to regional disruptions, changing trade policies, and tariff uncertainty.
Key Peptide Synthesis Market Segment Insights
- API type: Generic APIs are expected to retain the largest market share, supported by patent expirations for first-generation peptide drugs and demand for lower-cost alternatives to branded therapies. Synthesis method: Chemical synthesis currently dominates due to its scalability, flexibility, cost profile, and widespread commercial adoption. Chemical synthesis technology: Solid phase synthesis holds the leading share, while hybrid phase synthesis is projected to grow faster as development pipelines shift toward longer and more complex peptide sequences. Scale of operation: Commercial-scale manufacturing accounts for the largest share and is expected to register strong growth, driven by high-volume GMP-grade peptide API production and long-term supply agreements. Company size: The market includes small, mid-sized, large, and very large peptide manufacturers serving preclinical, clinical, and commercial requirements.
Regional Peptide Synthesis Market Outlook
Europe is projected to maintain the largest share of global peptide synthesis market revenue through 2035. The region benefits from extensive manufacturing capacity, active clinical research, established life sciences clusters, and strong academic-industry collaboration. Belgium remains a major contributor due to its biotechnology ecosystem, government support, and pharmaceutical logistics infrastructure. Switzerland is another important market, supported by Bachem's manufacturing presence and the country's integrated life sciences sector.
Asia-Pacific is forecast to register the highest CAGR during the forecast period. Growth is being driven by government investment in life sciences, expanding pharmaceutical demand, skilled labor availability, and cost-competitive manufacturing. Regional companies, including WuXi STA, are strengthening Asia-Pacific's position in global peptide API production.
Competitive Landscape
Companies evaluated in the peptide synthesis market include Amneal Pharmaceuticals, Asymchem, Aurisco Pharma, Dr. Reddy's Laboratories, Hybio Pharmaceutical, JYMed Peptide, Neuland Labs, Sinopep-Allsino Biopharmaceutical, SK Pharmteco, and WuXi STA, a WuXi AppTec company. The competitive assessment also examines peptide API manufacturers across North America, Europe, Asia-Pacific, and other international markets.
Research Coverage
The market report provides peptide synthesis market sizing and forecasts by API type, synthesis method, chemical synthesis technology, operating scale, company size, and geography. It also includes company benchmarking, manufacturer profiles, facility and capacity analysis, clinical trial assessment, demand forecasting, partnership analysis, recent industry developments, and regional manufacturing capability evaluation.
Additional analysis covers make-versus-buy decision frameworks, potential strategic partners, total cost of ownership over a 20-year period, and the strengths, weaknesses, opportunities, and threats affecting peptide API manufacturers and CDMOs. The research incorporates perspectives from senior industry stakeholders in Germany, the United States, Ireland, Japan, and India.
The report is designed to support pharmaceutical companies, biotechnology developers, investors, peptide CDMOs, distribution partners, service providers, and other stakeholders seeking data-driven insight into market growth, manufacturing demand, capacity constraints, competitive positioning, and emerging opportunities through 2035.
Report Benefits
- Detailed revenue projections for the global market and key subsegments Analysis of market drivers, barriers, trends, risks, and growth opportunities Competitive intelligence covering established manufacturers and emerging entrants Complementary presentation and Excel data packs Up to 15% complimentary content customization Research team walkthrough and a complimentary update for reports more than six months old
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment